The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: A model-based analysis

AIDS

Volumn 26, Issue 8, 2012, Pages 987-995

  Andrews, Jason R ^a,b,d   Lawn, Stephen D ^e,f   Rusu, Corina ^a,c   Wood, Robin ^e   Noubary, Farzad ^a,c,d   Bender, Melissa A ^g   Horsburgh, C Robert ^h   Losina, Elena ^a,b,c,d,h,i   Freedberg, Kenneth A ^a,b,c,d,h,j   Walensky, Rochelle P ^a,b,c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Division of General Medicine   (United States)

^d HARVARD UNIVERSITY   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BOSTON UNIVERSITY   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RIFAMPICIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MICROSCOPY; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SIMULATION; SOUTH AFRICA; TUBERCULOSIS;

ADULT; ANTI-RETROVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MASS SCREENING; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84861096884     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283522d47     Document Type: Article

References (38)

1. World Health Organization Global Tuberculosis Control 2011. Geneva. (2011). http://www.who.int/tb/publications/global-report/en/index.html. [Accessed 9 January 2012].
2. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-829; doi:10.1086/656282.
3. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker L-G, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24:1323-1328; doi:10.1097/QAD.0b013e3283390dd1.
4. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: Individual participant data meta-analysis of observational studies. PLoS Med 2011; 8:e1000391; doi:10.1371/journal.pmed.1000391.
5. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015; doi:10.1056/NEJMoa0907847.
6. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 2011; 377:1495-1505; doi:10.1016/S0140-6736(11)60438-8.
7. Lawn SD, Brooks SV, Kranzer K, Nicol M, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: A prospective study. PLoS Medicine 2011; 8:e1001067.
8. Lawn SD, Nicol MP. Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6:1067-1082; doi:10.2217/fmb.11. 84.
9. Walensky RP, Wood R, Ciaranello AL, Paltiel AD, Lorenzana SB, Anglaret X, et al. Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: A model-based analysis. PLoS Med 2010; 7:e1000382; doi:10.1371/journal.pmed.1000382.
10. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, et al. Scaling up antiretroviral therapy in South Africa: The impact of speed on survival. J Infect Dis 2008; 197:1324-1332; doi:10.1086/587184.
11. Hunink M, Glasziou P, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein M. Decision making in health and medicine: Inte-grating evidence and values. Cambridge: University Press; 2001
12. World Health Organization. Geneva, Switzerland: Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health; 2001; eport No. 2001/13984.
13. Department of Health. National Department of Health. Clinical Guidelines for the Management of HIV&AIDS in Adults and Adolescents. The South African antiretroviral treatment guidelines. Pretoria (2010). http://www.fidssa.co.za/ Guidelines/2010-Adult-ART-Guidelines.pdf. (Accessed 23 February 2012).
14. Jones-López EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, et al. Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: A prospective cohort study. PLoS Med 2011; 8:e1000427; doi:10.1371/journal.pmed. 1000427.
15. Cox HS, McDermid C, Azevedo V, Muller O, Coetzee D, Simpson J, et al. Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa. PLoS One 2010; 5:e13901; doi:10.1371/journal.pone.0013901.
16. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resourcelimited settings. Clin Chest Med 2009; 30:685-699; viii. doi:10.1016/j.ccm.2009.08.010.
17. Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008; 22:2527-2533; doi:10.1097/QAD.0b013e328311ac4e.
18. World Health Organization. Global Tuberculosis Control 2010. Geneva, Switzerland (2010). http://www.who.int/tb/publica tions/global-report/2010/en/. (Accessed 23 Februsary 2012).
19. Seung KJ, Omatayo DB, Keshavjee S, Furin JJ, Farmer PE, Satti H. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS ONE 2009; 4:e7186; doi:10.1371/journal.pone.0007186.
20. Brust JCM, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, et al. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. PLoS ONE 2011; 6:e15841; doi:10.1371/journal.pone.0015841.
21. Heller T, Lessells RJ, Wallrauch CG, Bärnighausen T, Cooke GS, Mhlongo L, et al. Community-based treatment for multidrugresistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2010; 14:420-426.
22. Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: Effect on immunological and virological outcome measures -a meta-analysis. Int J STD AIDS 2008; 19:291-296; doi:10.1258/ijsa.2007.007248.
23. Dimairo M, MacPherson P, Bandason T, Zezai A, Munyati SS, Butterworth AE, et al. The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: A 12-month cohort study in Harare, Zimbabwe. PLoS ONE 2010; 5:e11849; doi:10.1371/journal.pone.0011849.
24. National Health Laboratory Service (2009). Cost Quotation.
25. World Health Organization. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB; Geneva: World Health Organization. (2010). http://www.who.int/tb/laboratory/roadmap-xpert-mtb-rif.pdf. [Accessed 27 September 2011].
26. Clinton Health Access Initiative. Antiretroviral (ARV) Price List. (2010). http://www.clintonfoundation.org/files/chai-arv-price List-april2010-english.pdf. [Accessed 27 September 2011].
27. Department of Health. The South African Tuberculosis Control Programme Practical Guidelines. (2000). http://www.kznhealth. gov.za/chrp/documents/ Guidelines/Guidelines%20National/Tuberculosis/SA%20TB%20Guidelines%202004.pdf. [Accessed 27 September 2011].
28. Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: Implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42:464-469; doi:10.1097/01.qai.0000225729.79610.b7.
29. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings; Geneva: World Health Organization. (2010). http://www.who.int/hiv/pub/tb/9789241500708/en/index.html. [Accessed 27 September 2011].
30. Badri M, Cleary S, Maartens G, Pitt J, Bekker L-G, Catherine O, Wood R, et al. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther (Lond) 2006; 11:63-72.
31. Sinanovic E, Kumaranayake L. Financing and cost-effectiveness analysis of public-private partnerships: Provision of tuberculosis treatment in South Africa. Cost Eff Resour Alloc 2006; 4:11; doi:10.1186/1478-7547-4-11.
32. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, et al. Should resistance testing be performed for treatmentnaive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41:1316-1323; doi:10.1086/496984.
33. Banada PP, Sivasubramani SK, Blakemore R, Boehme C, Perkins MD, Fennelly K, Alland D. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to pointof-care settings. J Clin Microbiol 2010; 48:3551-3557; doi:10.1128/JCM.01053-10.
34. Pablos-Méndez A, Sterling TR, Frieden TR. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996; 276:1223-1228.
35. Kramer F, Modilevsky T, Waliany AR, Leedom JM, Barnes PF. Delayed diagnosis of tuberculosis in patients with human immunodeficiency virus infection. Am J Med 1990; 89:451-456.
36. Tostmann A, Kik SV, Kalisvaart NA, Sebek MM, Verver S, Boeree MJ, van Soolingen D. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 2008; 47:1135-1142; doi:10.1086/591974.
37. Vassall A, van Kampen S, Sohn H, Michael JS, John KR, den Boon S, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: A cost-effectiveness analysis. PLoS Med 2011; 8:e1001120; doi:10.1371/journal. pmed.1001120.
38. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test; Geneva. (2011). http://www.whq libdoc.who.int/publications/ 2011/9789241501569-eng.pdf. [Accessed 12 January 2012].